Analysis of the clinical application of Valganciclovir in preventing cytomegalovirus infection

Valganciclovir (Valganciclovir) is an oral antiviral drug that is a prodrug of ganciclovir (Ganciclovir). It can be rapidly metabolized into the active form in the body and inhibits the replication of cytomegalovirus (CMV). It inhibits viral DNApolymerase, preventing CMV from synthesizing DNA, thereby blocking viral proliferation. CMV infection is a common and serious complication in patients with organ transplantation and immunocompromised patients. The application of Vancevir provides an effective means for clinical prevention and treatment.

In organ transplant patients, Vancevir is often used to prevent CMV infection, especially in high-risk groups, such as patients whose donors are CMV positive and recipients CMV negative (D+/R-). Clinical studies have shown that oral prophylactic treatment with Vancevir given early after surgery can significantly reduce the incidence of CMV infection, reduce the complications of viral diseases, and improve transplant survival rate. The routine preventive regimen usually starts on the first day after surgery, once a day, and the dose is adjusted according to renal function, and lasts for 3 to 6 months or extended according to individual risks.

In non-transplant patients with low immune function, such as HIV infection, long-term use of immunosuppressants or chemotherapy, Vancevir can also be used for CMV prevention. By inhibiting viral replication, it can effectively reduce the incidence of serious infections such as CMV-related retinitis, pneumonia or enteritis, thereby protecting organ function and maintaining patients' quality of life. During use, blood and liver and kidney functions need to be monitored regularly to prevent drug-related toxicity.

Overall, Vancevi is effective in preventingCMVIt has important clinical value in the treatment of infections, especially for organ transplantation and high-risk immunosuppressed patients. Its oral administration is simple, its efficacy is clear, and it can effectively reduce CMV-related complications. In clinical application, the dose needs to be adjusted individually according to the patient's renal function and infection risk, and blood images and viral load must be monitored regularly to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/